Completed PHASE1 INTERVENTIONAL 2-arm NCT03576508

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza®) in Subjects With Painful Knee Osteoarthritis

Sponsor: Centrexion Therapeutics

Conditions Knee Osteoarthritis

Interventions CNTX-4975-05 Lidocaine (without epinephrine) Qutenza

Updated 6 times since 2018 Last updated: Nov 13, 2018 Started: Jun 25, 2018 Primary completion: Sep 6, 2018 Completion: Sep 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Knee Osteoarthritis, this trial is completed. The trial is conducted by Centrexion Therapeutics and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Oct 2018 — Dec 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centrexion Therapeutics

Data source: Centrexion Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States